Does Blue Cross Blue Shield of Minnesota Cover Ozempic?

How BCBS MN Classifies Ozempic on Its Formulary

Blue Cross Blue Shield of Minnesota places Ozempic (semaglutide injection, 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses) on its drug formulary under the GLP-1 receptor agonist class. On most commercial plans, the drug sits at a preferred-brand or non-preferred-brand tier, which means a higher copay than generics but lower than specialty-tier medications. The exact tier varies by plan: fully insured small-group products often list Ozempic at Tier 3, while self-funded employer plans can customize placement.

Formulary tier matters because it directly controls what you pay at the pharmacy counter. A Tier 3 preferred-brand copay on a typical BCBS MN Blue Cross Complete plan runs $50 to $75 per fill, while a Tier 4 non-preferred placement pushes the copay to $100 to $150 or switches to 30% to 40% coinsurance after deductible 1. Novo Nordisk reports that the wholesale acquisition cost (WAC) of Ozempic is approximately $935.77 per month for all pen strengths 2. Patients without any insurance coverage face that full list price. BCBS MN updates its formulary at least once per quarter, so checking the most current preferred drug list on the BCBS MN member portal before filling is worth the two minutes it takes.

The American Diabetes Association (ADA) 2024 Standards of Care recommend GLP-1 receptor agonists as a preferred second-line therapy for adults with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk 3. That guideline recommendation strengthens the clinical case when requesting coverage.

Prior Authorization Requirements for Ozempic

Nearly every BCBS MN plan requires prior authorization (PA) before the pharmacy will dispense Ozempic. The PA process confirms that the prescription meets the plan's medical necessity criteria. Your prescribing clinician, not you, submits the PA request.

BCBS MN's standard PA criteria for Ozempic typically require all of the following: a confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x), a recent HbA1c value of 7.0% or higher documented in the medical record, and evidence that the patient has tried and either failed or cannot tolerate metformin at a maximally tolerated dose 4. Some plans add a second step-therapy gate, requiring a documented trial of a sulfonylurea or SGLT2 inhibitor before approving a GLP-1 agonist. The insurer typically processes PA requests within 72 hours for standard requests and 24 hours for urgent requests.

If the PA is denied, BCBS MN allows a two-level appeal. Dr. Robert Gabbay, Chief Scientific and Medical Officer at the ADA, has stated: "Prior authorization requirements for evidence-based diabetes therapies create barriers that delay necessary care and worsen glycemic outcomes" 5. Tracking your HbA1c trajectory and documenting medication trials in the chart before your clinician submits the PA increases approval rates significantly.

A peer-reviewed analysis published in Diabetes Care found that 24.4% of initial PA requests for GLP-1 receptor agonists were denied across commercial insurers, though 61% of those denials were overturned on appeal 6. Submitting a complete request on the first attempt, with lab results and medication history attached, reduces the chance of an initial denial.

Step Therapy: What You Need to Try First

Step therapy (sometimes called "fail first") is a cost-management tool that BCBS MN applies to high-cost brand medications. For Ozempic, the most common step-therapy sequence requires a trial of metformin (typically 1,500 to 2 to 000 mg daily for at least 90 days) before the plan will authorize a GLP-1 receptor agonist.

Some BCBS MN employer-sponsored plans layer additional steps. A second-line requirement might mandate a 90-day trial of a sulfonylurea (glipizide, glimepiride) or an SGLT2 inhibitor (empagliflozin, dapagliflozin). Patients with documented contraindications to metformin (eGFR <30 mL/min/1.73 m², history of lactic acidosis, severe GI intolerance) can request a step-therapy exception, which bypasses the metformin requirement entirely 7.

The clinical rationale for trying metformin first is straightforward: it remains the least expensive oral diabetes medication, costing $4 to $15 per month at most pharmacies, and the ADA still lists it as first-line therapy for most adults with type 2 diabetes 3. If your HbA1c remains above target after a genuine metformin trial, the transition to Ozempic becomes both clinically appropriate and easier to authorize.

Coverage Differences Across BCBS MN Plan Types

Not all BCBS MN plans are identical. Coverage for Ozempic varies depending on whether you carry a fully insured individual/family plan, an employer-sponsored self-funded plan, a Medicare Advantage plan, or a Medicaid managed-care product.

Commercial fully insured plans. These follow the BCBS MN standard formulary. Ozempic is covered with PA at a preferred-brand or non-preferred-brand tier. Cost-sharing typically ranges from $50 to $150 per fill after deductible.

Self-funded employer plans. Employers that self-insure can customize every aspect of the formulary. Some exclude GLP-1 agonists entirely to control pharmacy spend, while others cover them with minimal barriers. Your Summary of Benefits and Coverage (SBC) document is the authoritative source for self-funded plans.

Medicare Advantage (Part D). BCBS MN offers Medicare Advantage plans through its Blue Cross Medicare Advantage brand. Ozempic is coverable under Part D when prescribed for type 2 diabetes. Under the Inflation Reduction Act (IRA), Medicare Part D out-of-pocket costs are capped at $2,000 annually as of 2025, which limits total Ozempic spending for Medicare enrollees 8. A critical distinction: Medicare Part D does not cover Ozempic when prescribed solely for weight management, because anti-obesity medications remain excluded from the Part D benefit by statute. The Treat and Reduce Obesity Act, if passed, would change this exclusion, but it has not been enacted as of May 2026.

Minnesota Medical Assistance (Medicaid). Minnesota's fee-for-service Medicaid program covers Ozempic for type 2 diabetes with PA. Managed-care organizations (MCOs) contracted with the state, including BCBS MN's public programs division, apply their own PA criteria, which may differ slightly from commercial plan rules 9.

Off-Label Use for Weight Loss: Will BCBS MN Pay?

This is where most coverage questions become complicated. Ozempic is FDA-approved exclusively for type 2 diabetes. It is not approved for chronic weight management. Wegovy (semaglutide 2.4 mg) holds the FDA obesity indication 2.

BCBS MN's standard commercial formulary does not cover Ozempic when prescribed off-label for weight loss in patients without type 2 diabetes. Pharmacies flag the rejection as "not covered for this indication." Some self-funded employer plans have added anti-obesity medication (AOM) benefits that include Wegovy or, less commonly, off-label Ozempic, but this is an employer-by-employer decision.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg (the Wegovy dose, not the Ozempic dose) produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo 10. The SELECT trial (N=17,604) showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease 11. These cardiovascular data led the AHA and ACC to recognize the cardiovascular benefit of semaglutide in patients with obesity and CVD. Despite this evidence, coverage for obesity indications remains inconsistent across payers.

If your primary goal is weight management, ask your clinician whether Wegovy is covered on your BCBS MN plan, because it carries the correct FDA indication and is more likely to be approved through the PA process for that purpose.

How to Reduce Your Out-of-Pocket Cost

Even with BCBS MN coverage, Ozempic copays can strain monthly budgets. Several strategies can lower what you actually pay.

Novo Nordisk Savings Card. Commercially insured patients (not Medicare, Medicaid, or other government programs) can use Novo Nordisk's savings offer to pay as little as $25 per 1- to 3-month supply for up to 24 months. The card covers up to $150 per fill in cost-sharing. This benefit restarts annually and can be combined with your insurance benefit.

Tier exception requests. If Ozempic sits at a non-preferred tier on your BCBS MN plan, your clinician can submit a formulary tier exception request arguing that you have tried and failed the preferred-tier alternatives. A successful exception moves the drug to a lower cost-sharing tier.

Mail-order pharmacy. BCBS MN plans that use Prime Therapeutics as their pharmacy benefit manager (PBM) often offer a 90-day mail-order supply at the cost of two copays instead of three, saving roughly 33% per fill cycle.

High-deductible plan strategy. If you carry a BCBS MN high-deductible health plan (HDHP) paired with a health savings account (HSA), Ozempic costs apply to your deductible dollar-for-dollar until the deductible is met. Using HSA funds keeps the spending tax-advantaged. In 2026, the IRS HSA contribution limit for family coverage is $8,550.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "The financial toxicity of branded diabetes medications is a clinical problem in itself, and clinicians should proactively discuss cost-reduction strategies at the point of prescribing" 12.

What to Do If Your BCBS MN Claim Is Denied

A denied claim or PA rejection is not the end of the process. BCBS MN provides a structured appeals pathway, and knowing how to use it improves your odds.

Step 1: Read the denial letter. BCBS MN is required to send a written explanation within 72 hours of a standard denial. The letter will cite the specific coverage rule or clinical criterion that was not met.

Step 2: Gather supporting documentation. Pull your HbA1c results (ideally two or more values over the past 12 months showing inadequate control on current therapy), a medication history showing prior drug trials, and any relevant specialist notes. A letter of medical necessity from your endocrinologist or primary care provider carries weight.

Step 3: File a first-level appeal. BCBS MN allows 180 days from the denial date to submit a first-level appeal. The appeal is reviewed by a physician who was not involved in the original denial. Include all supporting documentation and a clear explanation of why Ozempic is medically necessary for your specific clinical situation.

Step 4: External review. If the first-level appeal is denied, Minnesota law (Minn. Stat. § 62Q.73) grants you the right to an independent external review by a physician reviewer outside of BCBS MN 13. The external reviewer's decision is binding on the insurer.

The entire appeals process, from initial denial to external review resolution, typically takes 60 to 90 days. Starting the process quickly matters because gaps in GLP-1 therapy can lead to rebound hyperglycemia. A 2023 analysis found that patients who discontinued semaglutide regained approximately two-thirds of their initial weight loss within one year of stopping the medication 14.

Ozempic vs. Other Covered GLP-1 Options on BCBS MN

BCBS MN formularies typically include several GLP-1 receptor agonists, and switching to a preferred alternative can reduce cost without sacrificing clinical benefit.

Trulicity (dulaglutide) often sits at a preferred-brand tier on BCBS MN plans, making it $25 to $50 cheaper per fill than Ozempic. The AWARD trial program showed dulaglutide 1.5 mg reduced HbA1c by 1.1% to 1.5% from baseline across studies 15. Ozempic demonstrated a 1.5% to 1.8% HbA1c reduction in the SUSTAIN trials, suggesting modestly greater glucose-lowering efficacy 16.

Mounjaro (tirzepatide), a dual GIP/GLP-1 agonist, is covered on some BCBS MN plans and showed HbA1c reductions of up to 2.4% in the SURPASS trial program 17. Coverage and tier placement for Mounjaro varies more widely than for Ozempic because it is newer to market.

Rybelsus (oral semaglutide, 7 mg and 14 mg tablets) offers the same molecule as Ozempic in an oral formulation. Some patients prefer tablets over weekly injections. BCBS MN covers Rybelsus on most formularies, though it may sit at a different tier than injectable Ozempic. The PIONEER trials showed oral semaglutide 14 mg reduced HbA1c by 1.0% to 1.4% from baseline 18. The injectable form generally produces greater glucose lowering and weight loss at comparable doses.

If cost is the primary barrier, discussing a formulary-preferred GLP-1 alternative with your prescriber is a practical next step.